MedTrace Logo

A Study of Talazoparib in Patients With Advanced Solid Tumors

NCT03070548 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2018-12-17

Study results available
· View outcomes & findings →

Summary

This study will evaluate the mass balance of talazoparib after a single dose of talazoparib.

Conditions

Interventions

DRUG

Talazoparib

1 mg of talazoparib containing100 μCi of 14C-radiolabeled talazoparib

Sponsors & Collaborators

  • Medivation, Inc.

    collaborator INDUSTRY

  • Pfizer

    lead INDUSTRY

Principal Investigators

  • Pfizer Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-30
Primary Completion
2017-06-30
Completion
2017-06-30

Countries

  • Hungary

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03070548 on ClinicalTrials.gov